Management of Chronic Gastritis with Focal Intestinal Metaplasia
Test and eradicate H. pylori immediately, then determine surveillance strategy based on extent of intestinal metaplasia and individual risk factors. 1
Immediate Actions
1. H. pylori Testing and Eradication
- Test for H. pylori infection now using any validated method (urea breath test, stool antigen, or biopsy-based testing) 2
- Eradicate if positive - this is a strong recommendation with moderate quality evidence 2
- Confirm eradication after treatment completion 2
- H. pylori eradication reduces gastric cancer risk even in patients with established intestinal metaplasia 3
2. Risk Stratification Through Proper Endoscopic Assessment
You need to determine if this is "focal" (limited) or extensive intestinal metaplasia. The pathology report showing "antral mucosa with focal intestinal metaplasia" suggests limited disease, but this must be confirmed endoscopically and histologically. 1
Perform or ensure the index endoscopy included:
- High-definition white-light endoscopy with image enhancement (virtual chromoendoscopy) 1, 4
- Systematic biopsies from at least 2 separate sites:
- Any suspicious areas biopsied and labeled separately 1
If the initial endoscopy did NOT include corpus biopsies or was not high-quality, consider repeat endoscopy within 1 year for complete risk stratification - particularly if the patient has additional risk factors (see below). 2
Surveillance Decision Algorithm
NO Routine Surveillance Needed If:
- Intestinal metaplasia is limited to antrum only (confirmed by corpus biopsies showing no IM)
- AND no additional high-risk features present
- AND H. pylori has been eradicated 2
This represents the majority of patients with incidentally detected intestinal metaplasia in clinical practice. 2
Consider Surveillance Every 3 Years If ANY of the Following:
High-risk histologic features:
- Extensive intestinal metaplasia (involving both antrum AND corpus) - 2.1-fold increased risk 2
- Incomplete (colonic-type) intestinal metaplasia - 3.3-fold increased risk 2
- Severe atrophic gastritis on histology 1, 4
- Advanced OLGA/OLGIM staging (III/IV) if performed 4, 3
High-risk demographic/clinical features:
- Family history of gastric cancer in first-degree relative - 4.5-fold increased risk 2
- Racial/ethnic minorities (particularly Asian, Hispanic, Black populations) 2
- Immigrants from high gastric cancer incidence regions (East Asia, Eastern Europe, Central/South America) 2
- Persistent H. pylori infection despite treatment 4, 3
Surveillance Protocol When Indicated:
- Interval: Every 3 years (may consider shorter intervals with multiple risk factors) 1, 4
- Method: High-quality endoscopy with image enhancement and systematic biopsies 1
- Continue until age 80 or when comorbidities make treatment of early gastric cancer unlikely 4
Key Caveats and Pitfalls
The 2025 AGA update emphasizes more aggressive surveillance than the 2020 guidelines - particularly for patients with extensive disease, incomplete IM, or family history. The threshold for surveillance has effectively lowered. 1
"Focal" intestinal metaplasia is ambiguous - this pathology description doesn't tell you if corpus is involved. Without corpus biopsies, you cannot accurately risk-stratify this patient. 1, 2
Incomplete vs. complete intestinal metaplasia matters - ensure your pathologist documents this subtype, as incomplete IM carries 3.3-fold higher cancer risk. 2, 5 However, many U.S. pathologists don't routinely report this distinction. 2
Shared decision-making is critical when surveillance evidence is uncertain. Discuss that:
- Annual gastric cancer risk with IM is approximately 0.16% (1.6% over 10 years) 2
- Risk increases 2-4 fold with high-risk features
- Surveillance has uncertain benefit but potential harms (repeated procedures, biopsies, anxiety)
- No direct evidence proves surveillance reduces mortality 2
Do not perform short-interval repeat endoscopy routinely (within 1 year) unless the baseline endoscopy was inadequate or high-risk features warrant complete staging. 2